Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results

Last Modified: 3/13/2007 First Published: 4/21/2006


1.		Phase I/II Study of PXD101 in Patients With Unresectable Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				CTRG-HC06/21/05 NCI-7237, 7237, NCT00321594

Last Modified: 1/21/2008 First Published: 3/3/2006


2.		Phase II Study of PXD101 in Patients With Advanced Platinum-Resistant Ovarian Epithelial Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer or Micropapillary or Borderline (Low Malignant Potential) Ovarian Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				PMH-PHL-041 7267, NCI-7267, NCT00301756


3.		Clinical Trial of PXD101 in Patients With T-Cell Lymphomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				PXD101-CLN-6 NCT00274651

Last Modified: 4/2/2008 First Published: 7/23/2006


4.		Phase II Study of PXD101 in Patients With Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				MAYO-MC0581 7258, NCI-7258, NCT00357162

Last Modified: 1/5/2009 First Published: 12/24/2007


5.		Phase II Study of Belinostat in Patients With Recurrent or Metastatic, Unresectable Thymoma or Thymic Carcinoma Previously Treated With Prior Platinum-Containing Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				Over 18				NCI				NCI-08-C-0033 08-C-0033, 8174, NCT00589290, NCI-P07249

Last Modified: 10/24/2007 First Published: 6/23/2006


6.		Phase I Study of PXD101 and Bortezomib in Patients With Advanced Solid Tumors or Lymphomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				16 and over				NCI				UCHSC-05-0705 7281, NCI-7281, UCHSC-COMIRB-05-0705, NCT00348985

Last Modified: 4/17/2008 First Published: 5/23/2006


7.		Phase I Study of PXD101 and Isotretinoin in Patients With Metastatic or Unresectable Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				CCC-PHI-53 7251, NCI-7251, NCT00334789

Last Modified: 11/14/2008 First Published: 7/7/2006


8.		Phase I Partially Randomized Study of PXD101 and Azacitidine in Patients With Advanced Hematologic Cancers or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				UCCRC-14510A 14510A, 7285, NCI-7285, NCT00351975


9.		Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				PXD101-CLN-9 NCT00413075

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute